TNF and congestive heart failure: therapeutic possibilities

Bibliography

• COHN JN, LEVINE TB, OLIVARI MT et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl. I Med. (1984) 311(13):819–823.
   PubMed Web of Science ®Google Scholar
• MANN DL, KENT RL, PARSONS B, COOPER G IV: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation (1992) 85(2):790–804.
   PubMed Web of Science ®Google Scholar
• HELIN K, STOLL M, MEFFERT S, STROTH U, UNGER T: The role of angiotensin receptors in cardiovascular diseases. Ann. Med. (1997) 29(1):23–29.
   PubMed Web of Science ®Google Scholar
• HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation (2001) 104(24):2996–3007.
   PubMed Web of Science ®Google Scholar
• •Clinical guidelines for the treatment of heart failure.
   Google Scholar
• LEVINE B, KALMAN J, MAYER L, FILLIT HM, PACKER M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. (1990) 323(4):236–241.
   PubMed Web of Science ®Google Scholar
• •Early report suggesting a role of TNF-a in heart failure.
   Google Scholar
• KAPADIA S, LEE J, TORRE-AMIONE G, BIRDSALL HH, MA TS, MANN DL: Tumor necrosis factor-a gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. (1995) 96(2):1042–1052.
   PubMed Web of Science ®Google Scholar
• MANN DL: Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu. Rev. Physic] (2003) 65:81–101.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on cytokines and heart failure.
   Google Scholar
• PALMIERI EA, BENINCASA G, DI RELLA F et al: Differential expression of TNF-a, IL-6, and IGF-1 by graded mechanical stress in normal rat myocardium. Am. J. Physiol Heart Circ. Physic] (2002) 282(3):H926–H934.
   Web of Science ®Google Scholar
• BAUMGARTEN G, KNUEFERMANN P, KALRA D et al.: Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation (2002) 105(18):2192–2197.
   PubMed Web of Science ®Google Scholar
• BRASIER AR, JAMALUDDIN M, HAN Y, PATTERSON C, RUNGE MS: Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-KB (NF-1(13) transcription factor. MM. Cell. Biochem. (2000) 212(1-2):155–169.
   PubMed Web of Science ®Google Scholar
• TRACEY KJ, BEUTLER B, LOWRY SF et al.: Shock and tissue injury induced by recombinant human cachectin. Science (1986) 234(4775):470–474.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, KRIBBS SB, CLUBB FJ Jr et al.: Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats. Circulation (1998) 97(14):1382–1391.
   Google Scholar
• •Evidence that TNF-a reduces contractility at relevant concentrations.
   Google Scholar
• PAGANI FD, BAKER LS, HSI C, KNOX M, FINK MP, VISNER MS: Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-a in conscious dogs. J. Clin. Invest. (1992) 90(2):389–398.
   PubMed Web of Science ®Google Scholar
• MURRAY DR, FREEMAN GL: Tumor necrosis factor-a induces a biphasic effect on myocardial contractility in conscious dogs. Circ. Res. (1996) 78(1):154–160.
   PubMed Web of Science ®Google Scholar
• KUBOTA T, MCTIERNAN CE FRYE CS et al.: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-a. Circ. Res. (1997) 81(4):627–635.
   Google Scholar
• •Support for cardiac toxicity of TNF-a.
   Google Scholar
• DIBBS ZI, DIWAN A, NEMOTO S et al.: Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation (2003) 108(8):1002–1008.
   PubMed Web of Science ®Google Scholar
• KURRELMEYER KM, MICHAEL LH, BAUMGARTEN G et al.: Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc. Nat] Acad. Sci. USA (2000) 97(10):5456–5461.
   PubMed Web of Science ®Google Scholar
• MISRA A, HAUDEK SB, KNUEFERMANN P et al.: Nuclear factor-KB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation (2003) 108(25):3075–3078.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G, KAPADIA S, LEE J, BIES RD, LEBOVITZ R, MANN DL: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation (1995) 92(6):1487–1493.
   PubMed Web of Science ®Google Scholar
• MANN DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. (2002) 91(11):988–998.
   PubMed Web of Science ®Google Scholar
• ORAL H, DORN GW, MANN DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-a in the adult mammalian cardiac myocyte. Biol. Chem. (1997) 272(8):4836–4842.
   Web of Science ®Google Scholar
• KROWN KA, YASUI K, BROOKER MJ et al.: TNF a receptor expression in rat cardiac myocytes: TNF a inhibition of L-type Ca2' current and Ca2' transients. FEBS Lett. (1995) 376(1-2):24–30.
   PubMed Web of Science ®Google Scholar
• GULICK T, CHUNG MK, PIEPER SJ, LANGE LG, SCHREINER GF: Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte P-adrenergic responsiveness. Proc. Natl. Acad. Sci. USA (1989) 86(17):6753–6757.
   PubMed Web of Science ®Google Scholar
• KROWN KA, PAGE MT, NGUYEN C et al.: Tumor necrosis factor a-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. Clin. Invest. (1996) 98(12):2854–2865.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA T, NAKANO M, BEDNARCZYK JL, MCINTYRE BW, ENTMAN M, MANN DL: Tumor necrosis factor-a provokes a hypertrophic growth response in adult cardiac myocytes. Circulation (1997) 95(5):1247–1252.
   PubMed Web of Science ®Google Scholar
• LI YY, FENG YQ, KADOKAMI T et a]: Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor a can be modulated by anti-tumor necrosis factor a therapy. Proc. Natl. Acad. Sci. USA (2000) 97(23):12746–12751.
   PubMed Web of Science ®Google Scholar
• SETA Y, SHAN K, BOZKURT B, ORAL H, MANN DL: Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. (1996) 2(3):243–249.
   PubMedGoogle Scholar
• DES WAL A, PETERSEN NJ, FELDMAN AM, YOUNG JB, WHITE BG, MANN DL: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation (2001) 103(16):2055–2059.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G, KAPADIA S, BENEDICT C, ORAL H, YOUNG JB, MANN DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. (1996) 27(5):1201–1206.
   PubMed Web of Science ®Google Scholar
• •The basis of therapeutic anti-inflammatory strategies in heart failure.
   Google Scholar
• AUKRUST P, UELAND T, LIEN E et al.: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1999) 83(3):376–382.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, BENEDICT C, JOHNSTONE DE et al.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 82:1724–1729.
   PubMed Web of Science ®Google Scholar
• WEI GC, SIROIS MG, QU R, LIU P, ROULEAUJL: Subacute and chronic effects of quinapril on cardiac cytokine expression, remodeling, and function after myocardial infarction in the rat. J. Cardiovasc. Pharmaco] (2002) 39(6):842–850.
   PubMed Web of Science ®Google Scholar
• GULLESTAD L, AUKRUST P, UELAND T et al.: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll. Cardiol. (1999) 34(7):2061–2067.
   PubMed Web of Science ®Google Scholar
• GURLEK A, KILICKAP M, DINCER I, DANDACHI R, TUTKAK H, ORAL D: Effect of losartan on circulating TNFa levels and left ventricular systolic performance in patients with heart failure." Cardiovasc. Rick (2001) 8(5):279–282.
   Google Scholar
• PRABHU SD, CHANDRASEKAR B, MURRAY DR, FREEMAN GL: P-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation (2000) 101(17):2103–2109.
   PubMed Web of Science ®Google Scholar
• MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353(9169):2001–2007.
   PubMed Web of Science ®Google Scholar
• TSUTAMOTO T, WADA A, MATSUMOTO T et al.: Relationship between tumor necrosis factor-a production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. (2001) 37(8):2086–2092.
   PubMed Web of Science ®Google Scholar
• SLIWA K, SKUDICKY D, CANDY G, WISENBAUGH T, SARELI P: Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet (1998) 351(9109):1091–1093.
   PubMed Web of Science ®Google Scholar
• AGOSTON I, DIBBS ZI, WANG F et al.: Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. Card. Fail. (2002) 8(5):306–314.
   PubMed Web of Science ®Google Scholar
• GULLESTAD L, SEMB AG, HOLT E et al.: Effect of thalidomide in patients with chronic heart failure. Am. Heart J. (2002) 144(5):847–850.
   PubMed Web of Science ®Google Scholar
• SLIWA K, WOODIWISS A, KONE VN et al.: Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation (2004) 109(6):750–755.
   PubMed Web of Science ®Google Scholar
• KAPADIA S, TORRE-AMIONE G, YOKOYAMA T, MANN DL: Soluble TNF binding proteins modulate the negative inotropic properties of TNF-a M vitro. Am. I Physiol. (1995) 268(2 Pt 2):H517–H525.
   Google Scholar
• DESWAL A, BOZKURT B, SETA Y et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99(25):3224–3226.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, TORRE-AMIONE G, WARREN MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation (2001) 103(8):1044–1047.
   PubMed Web of Science ®Google Scholar
• ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. hat." Cardiol (2002) 86(2–3):123–130.
   Google Scholar
• ••Large randomised clinical trials ofTNF-a antagonism in heart failure.
   Google Scholar
• COLETTA AP, CLARK AL, BANARJEE P, CLELAND JG: Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur: J. Heart Fail (2002) 4(4):559–561.
   PubMed Web of Science ®Google Scholar
• ••Large randomised clinical trials ofTNF-a antagonism in heart failure.
   Google Scholar
• CHUNG ES, PACKER M, LO KH, FASANMADE AA, WILLERSON JT: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107(25):3133–3140.
   PubMed Web of Science ®Google Scholar
• HOFBAUER KH, SCHOOF E, KURTZ A, SANDNER P: Inflammatory cytokines stimulate adrenomedullin expression through nitric oxide-dependent and -independent pathways. Hypertension (2002) 39(1):161–167.
   PubMed Web of Science ®Google Scholar
• KATZ SD, RAO R, BERMAN JW et al: Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation (1994) 90(1):12–16.
   Google Scholar
• WONG GH, GOEDDEL DV: Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science (1988) 242(4880):941–944.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. J. Med. (2001) 345(23):1667–1675.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. J. Med. (2003) 349(20):1893–1906.53.PACKER M, CALIFF RM, KONSTAM MA et al: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 106(8):920–926.
   Google Scholar
• DUNSELMAN P, HJALMARSON A, KJEKSHUS J, MCMURRAY J, WAAGSTEIN F: The statin wars. Lancet (2003) 362(9398):185.Discussion 1856.
   Google Scholar
• GULLESTAD L, AASS H, FJELD JG et al:Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation (2001) 103(2):220–225.
   PubMed Web of Science ®Google Scholar